WJB001 + nedaplatin

WJB001 + nedaplatin is a combination of two antineoplastic agents under clinical investigation primarily for the treatment of cancers. **Nedaplatin** is a second-generation platinum-based chemotherapy agent designed to cause DNA cross-linking, leading to apoptosis of cancer cells; it is less nephrotoxic than cisplatin and is used in several solid tumors. The specific mechanism and details for "WJB001" are not identified in major references; therefore, the precise nature and properties of WJB001 are not described in current public domain sources. As a combination regimen, these drugs would be used synergistically to increase cytotoxic efficacy against cancer, typically administered intravenously. The main indication for similar nedaplatin regimens has been advanced non-small-cell lung cancer[1][2][3][4].